Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
221
datasets available to search
ShareScore release 0.9.0
Dataset results
221 results for “circulating tumor DNA”
Transposon DNA sequences facilitate the tissue-specific horizontal transfer of circulating tumor DNA between human cells
<p>The uploaded files are in the fasta format and are outputs from de novo assembly using the SGA algorithm (https://github.com/jts/sga). The description of the files are as below:</p> <table> <tbody> <tr> <td><strong>Filename</strong></td> <td><strong>description</strong></td> </tr> <tr> <td>772.final.fa</td> <td>Multiple Myeloma ctDNA</td> </tr> <tr> <td>54128-4M7.final.fa</td> <td>Pancreatic cancer cells coculture with multiple myeloma ctDNA</td> </tr> <tr> <td>54128-6MP.final.fa</td> <td>Multiple myeloma cells coculture with pancreatic cancer ctDNA</td> </tr> <tr> <td>MIA-Cells.final.fa</td> <td>Pancreatic cancer cells</td> </tr> <tr> <td>MIA-cells-with-P201812-2.final.fa</td> <td>Pancreatic cancer cells coculture with pancreatic cancer ctDNA</td> </tr> <tr> <td>MM1S-cells.final.fa</td> <td>Multiple Myeloma cells</td> </tr> <tr> <td>MM1S-cells-with-772-2.final.fa</td> <td>Mutiple myeloma cells coculture with Multiple myeloma ctDNA</td> </tr> <tr> <td>P201812-2.final.fa</td> <td>Pancreatic Cancer ctDNA</td> </tr> </tbody> </table>
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
ClinicalTrials.gov study NCT05757843. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
ClinicalTrials.gov study NCT06649838. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
ClinicalTrials.gov study NCT04254497. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
ClinicalTrials.gov study NCT05976932. IPD Sharing: NO. Countries: 0. Publications: 0.
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
ClinicalTrials.gov study NCT07132502. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
ClinicalTrials.gov study NCT02833467. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
ClinicalTrials.gov study NCT06050954. IPD Sharing: NO. Countries: 0. Publications: 0.
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
ClinicalTrials.gov study NCT05427617. IPD Sharing: NO. Countries: 0. Publications: 0.
Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: correlation with FDG-PET/CT
GEO Series GSE244989. Homo sapiens. 142 samples. Type: Genome variation profiling by high throughput sequencing.
Shotgun sequencing of 5-hydroxymethylcysotine circulating cell-free DNA from the blood distinguishes solid tumor tissues of origin
GEO Series GSE81314. Homo sapiens. 126 samples. Type: Methylation profiling by high throughput sequencing.
Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma
In this study, we evaluated circulating tumor DNA (ctDNA) as a biomarker in the serum of 124 patients with newly diagnosed intermediate risk rhabdomyosarcoma (IR RMS) from the Children's Oncology Group (COG) biorepository. In addition to pre-treatment serum, we also analyzed matched tumor tissue and germline in a subset of patients. We profiled samples using ultra-low passage whole genome sequencing (ULP-WGS) and a new custom hybrid-capture sequencing assay, Rhabdo-Seq, to detect copy number alterations, rearrangements, and single nucleotide variants. We found that patients with detectable ctDNA at diagnosis had significantly worse outcomes than those without detectable levels of ctDNA. Our study demonstrates that baseline ctDNA detection is feasible and prognostic in IR RMS. The ULP-WGS and targeted next-generation sequencing (Rhabdo-Seq and TranSS-Seq) data are available in this study.
Circulating Tumor DNA Sequencing Provides Comprehensive Mutation Profiling for Pediatric Central Nervous System Tumors
Tumor molecular profiling is increasingly important for the diagnosis and clinical management of childhood brain tumors, including diffuse midline glioma (DMG). We established a targeted deep sequencing approach using the TruSight Oncology 500 ctDNA exome panel to detect tumor genomic mutations and copy number variations in circulating tumor DNA from children diagnosed with DMG. In this study, we present the sensitivity, specificity, and clinical implications of our liquid biopsy sequencing approach for tumor genome profiling in children with DMG.
Dataset related to article "Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer"
<p>This record contains raw data related to article<strong> "</strong>Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer<strong>".</strong></p> <p>We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and ultimately will confer resistance. In this proof of principle study, the same genomic libraries obtained at the diagnosis (T0), TRm and TRc were further analyzed by targeted resequencing approach to sequence the coding region of a panel of 65 genes to provide longitudinal analysis of clonal evolution as a novel strategy to support clinical decisions for the second-line treatment. Experiments were performed on plasma and tumor tissues withdrawn on a selection of previously analyzed cohorts of cases (i.e., 33 matched primary and synchronous lesions and 43 plasma samples from 18 patients). At T0, the median concordance of mutations shared by each tumor tissue biopsy and its matched plasma sample was 2.27%. This finding confirms the limit of a single tumor biopsy to be representative of the entire disease, while plasma analysis can recapitulate most of the main molecular lesions of the disease. A comparable scenario was observed during longitudinal analysis, where, with the exception of the <em>TP53</em> gene and germline mutations in <em>BRCA1/2</em> genes, no other gene shared the same locus specific gene mutation across T0, TRm and TRc time points. This high level of temporal heterogeneity has important implications for planning second-line treatment. For example, in three out of 13 cases, plasma ctDNA analysis at TRm or TRc reported acquired novel variants in the <em>TP53BP1</em> gene not present at T0. In particular, patient 21564, potentially eligible for PARP-inhibitor (PARPi) treatment at the time of diagnosis (<em>BRCA1</em> c.5182delA mutation), would unlikely respond to these drugs in second-line therapy due to the presence of eight distinct <em>TP53BP1</em> variants in plasma samples collected TRc. This study demonstrates that liquid biopsy provides a real-time molecular picture to intercept those actionable genetic vulnerabilities or drug resistance mechanisms that could be used to plan a more rational second-line treatment.</p>
Genome-wide methylation analysis of cerebrospinal fluid circulating tumor DNA: a new biomarker for recurrent glioblastoma
GEO Series GSE205514. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing; Methylation profiling by high throughput sequencing.
Genome-wide methylation analysis of cerebrospinal fluid circulating tumor DNA: a new biomarker for recurrent glioblastoma [MeDIP-Seq]
GEO Series GSE205513. Homo sapiens. 7 samples. Type: Methylation profiling by high throughput sequencing.
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors
GEO Series GSE210323. Homo sapiens. 2 samples. Type: Genome variation profiling by array.
Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma [mRNA-Seq]
GEO Series GSE205590. Homo sapiens. 3 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma [MeDIP-Seq]
GEO Series GSE205519. Homo sapiens. 8 samples. Type: Methylation profiling by high throughput sequencing.
Genome-wide methylation analysis of cerebrospinal fluid circulating tumor DNA: a new biomarker for recurrent glioblastoma [mRNA-Seq]
GEO Series GSE205512. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.